Erratum to: FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity [Immunogenetics, 65, (2013) 265-271, DOI 10.1007/s00251-013-0679-8];FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity

Immunogenetics

Volumn 65, Issue 4, 2013, Pages 265-271

  Moroi, Rintaro ^a,c   Endo, Katsuya ^a   Kinouchi, Yoshitaka ^a   Shiga, Hisashi ^a   Kakuta, Yoichi ^a   Kuroha, Masatake ^a   Kanazawa, Yoshitake ^a   Shimodaira, Yosuke ^a   Horiuchi, Takahiko ^b   Takahashi, Seiichi ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c not available   (Japan)

Author keywords

ADCC; Crohn's disease; FCGR3A; Infliximab; Polymorphism

Indexed keywords

C REACTIVE PROTEIN; FC RECEPTOR; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG RESPONSE; EFFECTOR CELL; FCGR3A GENE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; JAPANESE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 84876502612     PISSN: 00937711     EISSN: 14321211     Source Type: Journal    
DOI: 10.1007/s00251-015-0861-2     Document Type: Erratum

References (24)

1. Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F (2009) Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68:1547-1552
2. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
3. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446
4. Congy-Jolivet N, Bolzec A, Ternant D, Ohresser M, Watier H, Thibault G (2008) Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158 V allotype. Cancer Res 68:976-980
5. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64:4664-4669
6. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163-196
7. Harashima S, Horiuchi T, Hatta N, Morita C, Higuchi M, Sawabe T, Tsukamoto H, Tahira T, Hayashi K, Fujita S, Niho Y (2001) Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 166:130-136
8. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP (2007) Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110:2561-2564
9. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M (1997) Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48 L/R/H phenotype. Blood 90:1109-1114
10. Louis E, El Ghoul Z, Vermeire S (2004) Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J. F., and Watier, H.: Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 19:511-519
11. Louis EJ, Watier HE, Schreiber S, Hampe J, Taillard F, Olson A, Thorne N, Zhang H, Colombel JF (2006) Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 16:911-914
12. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
13. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M (2008) Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 58:1248-1257
14. Mossner R, Schon MP, Reich K (2008) Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol 26:486-502
15. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405
16. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358:295-296
17. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029-1035
18. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244-279
19. Tsukahara S, Ikari K, Sato E, Yamanaka H, Hara M, Tomatsu T, Momohara S, Kamatani N (2008) A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67:1791-1792
20. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D (2005) Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 52:2693-2696
21. Vance BA, Huizinga TW, Wardwell K, Guyre PM (1993) Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. J Immunol 151:6429-6439
22. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947
23. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP (1997) A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100:1059-1070
24. Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE (2009) The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113:3735-3743